Clinical Trials Browser

Prostatic Neoplasms × Trastuzumab × 90 days × Clear all

NCT05730712 2026-02-06

Pertuzumab, Trastuzumab, Hyaluronidase-zzxf and Enzalutamide for Treatment of Metastatic Castration-Resistant Prostate Cancer

Phase 2 Completed

Prostatic Neoplasms